Description
P4pal10 is a pepducin antagonist of proteinase-activated receptor 4 (PAR4) and formyl peptide receptor 2 (FPR2), as well as an agonist of free fatty acid receptor 2 (FFAR2/GPR43).1,2 It is composed of a peptide that corresponds to the third intracellular loop of human PAR4 that is conjugated to palmitic acid (Item No. 10006627).1 P4pal10 selectively inhibits the aggregation of isolated human platelets induced by the PAR4 peptide agonist AYPGKF-NH2 (Item No. 24258; IC50 = 0.5-1 µM) over the PAR1 peptide agonist SFLLRN-NH2 (Item No. 36881), the TP receptor agonist U-46619 (Item No. 16450), the platelet glycoprotein Ib (GPIb), GPIX, and GPV agonist ristocetin, ADP (Item No. 21121), or collagen at 5 µM. It inhibits increases in intracellular calcium induced by the FPR1 and FPR2 agonist WKYMVm but not by the FPR1 agonist fMLF in isolated human neutrophils and induces superoxide production in TNF-α primed isolated human neutrophils stimulated with the FFAR2 allosteric modulator Cmp58.2 P4pal10 (1, 3, or 10 µg/kg) reduces myocardial infarct size in a rat model of coronary artery ligation-induced ischemia-reperfusion injury.3 It increases the paw withdrawal threshold in rat models of osteoarthritis induced by monoiodoacetate injection into the knee joint or medial meniscal transection.4WARNING This product is not for human or veterinary use.
References
[1] LIDIJA COVIC. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation[J]. Nature Medicine, 2002, 8 10: 1161-1165. DOI:
10.1038/nm760[2] ANDRÉ HOLDFELDT . The PAR4-derived pepducin P4Pal10 lacks effect on neutrophil GPCRs that couple to Gαq for signaling but distinctly modulates function of the Gαi-coupled FPR2 and FFAR2[J]. Biochemical pharmacology, 2020, 180: Article 114143. DOI:
10.1016/j.bcp.2020.114143[3] JENNIFER L STRANDE. Inhibiting protease-activated receptor 4 limits myocardial ischemia/reperfusion injury in rat hearts by unmasking adenosine signaling.[J]. ACS Applied Electronic Materials, 2008: 1045-1054. DOI:
10.1124/jpet.107.133595[4] MELISSA S O’BRIEN Jason J M. Targeting Proteinase Activated Receptor-4 Reduces Mechanonociception During the Acute Inflammatory Phase but not the Chronic Neuropathic Phase of Osteoarthritis in Rats.[J]. Frontiers in Pharmacology, 2021: 756632. DOI:
10.3389/fphar.2021.756632
